-
https://clinton.presidentiallibraries.us/files/original/1edc60e6ed4831f961c4ad6b9711546c.pdf
ceb7dc45a73cd6371389c7fec11a5ca4
PDF Text
Text
FOIA Number: 2006-0225-F
FOIA
This is not a textual record. This is used as an
administrative marker by the William J. Clinton
Presidential Library Staff.
Collection/Record Group:
Clinton Presidential Records
Subgroup/Office of Origin:
Records Management - SUBJECT FILE
Series/Staff Member:
Subseries:
OA/ID Number:
10793
Scan ID:
040701
Document Number:
Folder Title:
HE
Stack:
Row:
Section:
Shelf:
Position:
s
84
6
9
1
�ID# 040701
THE WHITE HOUSE
CORRESPONDENCE TRACKING WORKSHEET
INCOMING
1-f&
DATE RECEIVED: OCTOBER 19, 1993
NAME OF CORRESPONDENT: THE HONORABLE DIANNE FEINSTEIN
SUBJECT: EXPRESSES CONCERNS REGARDING THE EFFECTS OF
THE HEALTH CARE PACKAGE ON THE BIOTECHNOLOGY
FIRMS OF CALIFORNIA
ACTION
ROUTE TO:
OFFICE/AGENCY
DISPOSITION
ACT
DATE
CODE YY/MM/DD
(STAFF NAME)
HOWARD PASTER
REFERRAL NOTE:
HOWARD PASTER
REFERRAL NOTE:
TYPE
RESP
ORG
93/10/13 HP
A 93/10/13
RSR
93/10/19
S:- tt'-1 I CJ I _Li) ~
IV
_!_!_
_!_!_
_ !_!_
REFERRAL NOTE:
REFERRAL NOTE:
REFERRAL NOTE:
C COMPLETED
D YY/MM/DD
- _!_!_
- _!_!_
- _!_! _
COMMENTS:
ADDITIONAL CORRESPONDENTS:
MAIL
USER CODES: (A)D CA
MEDIA:L
INDIVIDUAL CODES:
(B) _ _ __
1210
(C) _ _ __
***********************************************************************
*ACTION CODES:
*DISPOSITION
*OUTGOING
*
*
*
*CORRESPONDENCE:
*
*A-APPROPRIATE ACTION *A-ANSWERED
*TYPE RESP=INITIALS
*
*C-COMMENT/RECOM
*B-NON-SPEC-REFERRAL
*
OF SIGNER
*
*C-COMPLETED
*
CODE = A
*
*D-DRAFT RESPONSE
*COMPLETED = DATE OF
*
*F-FURNISH FACT SHEET *S-SUSPENDED
*I-INFO COPY/NO ACT NEC*
*
OUTGOING *
*
*
*R-DIRECT REPLY W/COPY *
*S-FOR-SIGNATURE
*
*
*
*
*
*
*X-INTERIM REPLY
***********************************************************************
REFER QUESTIONS AND ROUTING UPDATES TO CENTRAL REFERENCE
(ROOM 75,0EOB) EXT-2590
KEEP THIS WORKSHEET ATTACHED TO THE ORIGINAL INCOMING
LETTER AT ALL TIMES AND SEND COMPLETED RECORD TO RECORDS
MANAGEMENT.
'
~
�-
DIANNE FEINSTEIN
CALIFORNIA
.
COMMITTEE ON APPROPRIATIONS
'
COMMITTEE ON THE JUDICIARY
COMMITTEE ON RULES AND ADMINISTRATION
tinittd
~tatts ~matt
WASHINGTON, DC 20510-0504
October 7, 1993
The Honorable William Jefferson Clinton
President of the United States
The White House
Washington, D.C. 20500
Dear Mr. President:
I would
Lady for the
reform. You
dialogue and
like to congratulate and thank you and the First
leadership you are providing on national health care
have challenged us as a nation to engage in honest
as a government to cooperate across party lines.
As you prepare to introduce the Health Security Act to
Congress, I want to raise some concerns that biotechnology firms
in California have brought to my attention. They perceive that
the Act would regulate or control prices for new or breakthrough
drugs, which would stifle this emerging industry.
As you undoubtedly know, California is home to more than 800
biomedical firms that are engaged in discovering new ways to
prevent, diagnose, and treat life-threatening and seriously
debilitating diseases. The medical treatments these firms are
researching and developing have the potential of improving the
quality and longevity of life for many and reducing the costs of
medical intervention. Biotechnology is a high-wage, high-tech,
and innovative industry.
Because biotech firms are engaged primarily in discovering
new drugs, they require extensive investments in research and
development. Sales revenue is often small at first; some firms
are years away from introducing a drug to the market, and many
report annual losses. As a result, investing in biotech is risky.
Substantial hurdles have to be overcome before a new drug can be
marketed. The capital needs of biotech companies can only be met
if investors can foresee a return commensurate with the risks,
costs, and time involved in product development.
I ask you to consider the potential economic impact on job
creation, as well as the medical and cost saving benefits of
biotech products, when you are finalizing the Health Security Act.
Government oversight or regulation of new drug prices, as well as
exclusion of new drugs from government programs due to price,
could deter investors from biotech and encourage them to divert
their capital to other industries in which the risks are fewer and
the returns all but guaranteed.
�.:
Page 2
California has led the nation in efforts to improve health
care outcomes while controlling costs. One-third of Californians
are enrolled in health maintenance organizations that provide
affordable and quality managed care, and California's Medical
Injury Compensation Reform Act (MICRA) has produced a significant
decrease in the cost of medical malpractice insurance and related
instances of unnecessary tests and procedures. Californians have
pioneered health care reform, and with our experience and
technological know-how, Californians can certainly contribute to
the national reform.
Sincere:lZ,ly,
. c---- .
·!~
Dianne Feinstein
United States Senator
DF:plm
�•
'
.
THE WHITE HOUSE
WASHINGTON
October 13, 1993
Dear Senator Feinstein:
Thank you very much for your letter to President Clinton
concerning the effects of the health care package on the
biotechnology firms of California.
The President has been advised of your interest in this
matter and you should be hearing from him in the near future.
Please do not hesitate to contact me if I can be of further
assistance.
With best wishes,
Paster
to the President
slative Affairs
The Honorable Dianne Feinstein
United States Senate
Washington, D.C. 20510
�•
~
.,
.
•
'
.
THE WHITE HOUSE
WASHINGTON
October 13, 1993
MEMORANDUM FOR IRA MAGAZINER
PASTER(~
FROM:
HOWARD G.
SUBJECT:
BIOTECHNOLOGY AND HEALTH CARE
Attached is a copy of a letter sent to the President from Dianne
Feinstein (D-CA). I have also enclosed a copy of my
acknowledgement letter to her.
The President has requested that he see and sign every letter
going to Capitol Hill. We did not want to fully answer the
questions addressed in this letter without assistance from your
office; therefore, I would appreciate your office drafting a
response and returning it to LeeAnn Inadomi (WH-East Wing) within
48 hours. She will then print the letter in final form and have
the President sign the letter.
Thank you very much for your assistance. If you have any
questions, please feel free to call LeeAnn at 456-7500.
Attachments
�
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Correspondence between the White House and Congress concerning the Health Care Task Force
Creator
An entity primarily responsible for making the resource
White House Office of Records Management
Office of the Counsel to the President
Office of Policy Development
White House Health Care Interdepartmental Working Group
Date
A point or period of time associated with an event in the lifecycle of the resource
1993
Is Part Of
A related resource in which the described resource is physically or logically included.
<a href="http://clinton.presidentiallibraries.us/items/show/36142" target="_blank">Collection Finding Aid</a>
Identifier
An unambiguous reference to the resource within a given context
2006-0225-F
Description
An account of the resource
This collection contains White House correspondence to and from Congress concerning the Health Care Task Force between July 1993 to December 1993. The Task Force on National Health Care Reform was created by President Clinton in January 1993 and was charged with developing a comprehensive national health care reform package. The Task Force was chaired by First Lady Hillary Rodham Clinton. The majority of the congressional letters were written to express the concerns of constituents, as well as correspondence regarding the maintenance of the Health Care Task Force's records and requests by Congress to view those records.
Provenance
A statement of any changes in ownership and custody of the resource since its creation that are significant for its authenticity, integrity, and interpretation. The statement may include a description of any changes successive custodians made to the resource.
Clinton Presidential Records: White House Staff and Office Files
Publisher
An entity responsible for making the resource available
William J. Clinton Presidential Library & Museum
Extent
The size or duration of the resource.
83 folders in 2 boxes
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Original Format
The type of object, such as painting, sculpture, paper, photo, and additional data
Paper
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
40701
Creator
An entity primarily responsible for making the resource
White House Office of Records Management
Subject Files
HE
Identifier
An unambiguous reference to the resource within a given context
2006-0225-F
Is Part Of
A related resource in which the described resource is physically or logically included.
Box 1
<a href="http://www.clintonlibrary.gov/assets/Documents/Finding-Aids/2006/2006-0225-F.pdf" target="_blank">Collection Finding Aid</a>
<a href="https://catalog.archives.gov/id/1127666" target="_blank">National Archives Catalog Description</a>
Provenance
A statement of any changes in ownership and custody of the resource since its creation that are significant for its authenticity, integrity, and interpretation. The statement may include a description of any changes successive custodians made to the resource.
Clinton Presidential Records: White House Staff and Office Files
Publisher
An entity responsible for making the resource available
William J. Clinton Presidential Library & Museum
Format
The file format, physical medium, or dimensions of the resource
Adobe Acrobat Document
Medium
The material or physical carrier of the resource.
Reproduction-Reference
Date Created
Date of creation of the resource.
1/7/2015
Source
A related resource from which the described resource is derived
42-t-1127666-20060225F-001-033-2015
1127666